MAPS has received regulatory approval to conduct a study of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war.
MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. Food and Drug Administration.
Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986. NIDA's monopoly on the supply of marijuana for research and the DEA's refusal to allow researchers to grow their own has restricted medical marijuana research for decades. For over 12 years, MAPS was involved in legal struggles against the DEA to end this situation.
On March 14, 2014, the U.S. Public Health Service approved our study of smoked whole plant (botanical) marijuana for symptoms of PTSD in U.S. veterans. MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. On December 17, 2014, MAPS was awarded a $2 million grant from the state of Colorado to complete the study. We are currently waiting for DEA approval and anticipate starting the study in early 2016 at Johns Hopkins University and in Phoenix, Ariz.
See below for frequently updated information about completed, ongoing, or planned MAPS studies.
MAPS-Sponsored Medical Marijuana Research
Marijuana for Symptoms of PTSD (U.S.)
MAPS Efforts to Obtain a DEA License for a Medical Marijuana Production Facility
Medical Marijuana Research News